Development, production and characterization of SARS-CoV-2 virus-like particles (Coronaviridae: Orthocoronavirinae: Betacoronavirus: Sarbecovirus)
Authors:
- O E LatyshevOLO E Latyshev
- O N ZaykovaOZO N Zaykova
- O V EliseevaOEO V Eliseeva
- T E SavochkinaTST E Savochkina
- Y Y ChernoryzhYCY Y Chernoryzh
- A V SyroeshkinA V Syroeshkin
- G V PetrovG V Petrov
- G K VorkunovaGVG K Vorkunova
- V F LarichevVLV F Larichev
- I T FediakinaIFI T Fediakina
- S A CherepushkinSCS A Cherepushkin
- V V TsibezovVTV V Tsibezov
Open Access
- 6 May 2024
- journal article
- research article
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 69 (2) , 175-186
Abstract
Introduction. The COVID-19 pandemic caused by SARS-CoV-2 has created serious health problems worldwide. The most effective way to prevent the occurrence of new epidemic outbreaks is vaccination. One of the modern and effective approaches to vaccine development is the use of virus-like particles (VLPs). The aim of the study is to develop a technology for production of VLP based on recombinant SARS-CoV-2 proteins (E, M, N and S) in insect cells. Materials and methods. Synthetic genes encoding coronavirus proteins E, M, N and S were used. VLP with various surface proteins of strains similar to the Wuhan virus, Delta, Alpha and Omicron were developed and cloned into the pFastBac plasmid. The proteins were synthesized in the baculovirus expression system and assembled into VLP in the portable Trichoplusia ni cell. The presence of insertion in the baculovirus genome was determined by PCR. ELISA and immunoblotting were used to study the antigenic activity of VLP. VLP purification was performed by ultracentrifugation using 20% sucrose. Morphology was assessed using electron microscopy and dynamic light scattering. Results. VLPs consisting of recombinant SARS-CoV-2 proteins (S, M, E and N) were obtained and characterized. The specific binding of antigenic determinants in synthesized VLPs with antibodies to SARS-CoV-2 proteins has been demonstrated. The immunogenic properties of VLPs have been studied. Conclusion. The production and purification of recombinant VLPs consisting of full-length SARS-CoV-2 proteins with a universal set of surface antigens have been developed and optimized. Self-assembling particles that mimic the coronavirus virion induce a specific immune response against SARS-CoV-2.Keywords
This publication has 18 references indexed in Scilit:
- An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaquesSignal Transduction and Targeted Therapy, 2023
- First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2The Lancet Microbe, 2023
- COVID-19 vaccine development: milestones, lessons and prospectsSignal Transduction and Targeted Therapy, 2022
- T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variantCellular & Molecular Immunology, 2022
- Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2Biotechnology Letters, 2021
- Mechanisms of SARS-CoV-2 entry into cellsNature Reviews Molecular Cell Biology, 2021
- Safety and Efficacy of NVX-CoV2373 Covid-19 VaccineNew England Journal of Medicine, 2021
- Coronavirus biology and replication: implications for SARS-CoV-2Nature Reviews Microbiology, 2020
- Characteristics of SARS-CoV-2 and COVID-19Nature Reviews Microbiology, 2020
- A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiologyNature Microbiology, 2020